Reyon Pharmaceutical Co., Ltd

REYON

Anaesthetics; Anti-cancer preparations; Anti-inflammatory and antipyretic preparations; Antibiotics; Antihistamines; Antivirals; Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Diagnostic preparations for medical purposes; Diagnostic reagents and contrast media for medical use; Hormonal preparations; Hormones for medical purposes; Ocular pharmaceuticals; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for use in urology; Pharmaceutical products for treating respiratory diseases; Psychotropics; Therapeutic vaccines; Tumor suppressing agents; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents;